# A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression

> **NCT01640080** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 30 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Esketamine
- **DRUG:** Esketamine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01640080
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-27
- **Primary completion:** 2013-06-03
- **Final completion:** 2013-06-03
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01640080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01640080, "A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01640080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*